US Partnership Deal With Owen Mumford Announced

The partnership between Forte Medical and Owen Mumford USA was launched today at the OCTANe Medical Innovation Technology Forum (MTIF) at Newport Beach, CA 28-29 October 2019. 

Introducing Peezy Midstream to the USA has long been an ambition of Forte Medical. Our disruptive and innovative MedTech called for a partner with experience, knowledge and a savvy mindset. We found that partner in Atlanta-based Owen Mumford USA whose reach covers the USA and Canada and is managed by Travis Shaw.

Owen Mumford has been at the forefront of medical device innovation for over 65 years, creating solutions that improve the delivery of healthcare and home health treatments for people around the world. Their products span devices that make blood testing more comfortable to solutions that make it easier to administer life-saving medication.

Owen Mumford’s experience in medical devices began in the 1950s when founders Ivan Owen and John Mumford established the company. The company have direct sales offices and a network of distribution partners serving customers in over 60 countries, and employ over 800 people across the Americas, Europe and Asia.  

“Owen Mumford USA is delighted to partner Forte Medical in North America and Canada,” says Travis Shaw. “Our team looks forward to expanding our mutual synergies. Research indicates that Peezy Midstream can add significant clinical and cost value to healthcare providers, a true win-win for all parties.”
 
Thanks to the Greater Irvine Chamber of Commerce for making this possible.

urine infection medication

Comment On Incentivising Companies To Develop New Antibiotics

It is very interesting to read that pharma companies are to be incentivised to develop new antibiotics to combat antimicrobial resistance (AMR). A significant yet consistently overlooked contribution to the problem of AMR is unreliable urine collection and analysis, which leads to the staggeringly high rates of broad-spectrum antibiotic prescribing that is fuelling the AMR crisis.

NHS Improvement data confirms that 50% of the global rise in AMR has a urinary source and that Urinary Tract Infection (UTI) is being routinely treated with increasingly pointless broad spectrum antibiotics.

All NHS and Public Health England guidelines specify that midstream urine is required for accurate analysis. There is no guarantee that this occurs as there is no protocol for urine collection. We know from a 2016 FOI request to all NHS Trusts that urine specimen contamination rates reach as high as 70%, with an average of 23%. This means 15m people a year are not being accurately diagnosed and are generally prescribed a broad spectrum antibiotic that will not treat their condition.

Some years ago, in response to failed UTI treatment amongst his patients, a diligent NHS GP identified this problem and invented a low-cost, British made medical device that collects midstream urine specimens. It has taken almost 15 years for us to persuade the NHS that his device is worth using; clinical trial results confirm its efficacy and substantial cost savings due to reduced retesting and false-positive urine specimens. Our world-first device delivers win-win for diagnostics, clinicians, patients, AMR and NHS finances all for 87p. Can the pharma companies compete with this?

Before the Government “incentivises” the already well-off pharma industry to develop new medicines, it would do well to get the basics right and look to NHS generated innovation to help it succeed. As it happens, our British SME is looking for investment; perhaps the Government would instead like to incentivise our work in delivering a tangible, ready-made solution for this global problem?

Forte Medical Review

A Year In Review – 2018

  • New evidence showing a 70% reduction in false positive dipped specimens
  • Extended uptake by the NHS
  • Investment including a JV to create a Smart Peezy
  • Sheena Byrom joining our Advisory Panel
  • Being recognised in the Sunday Times 2018 Maserati 100 list that celebrate British entrepreneurship

These have been a few of our highlights for 2018 – to read more, please click here

Gionvanni Forte at no. 10

To No 10 for the LS Industrial Strategy Reception

Today, Forte Medical’s Chief Executive Giovanna Forte attended the Life Sciences Industrial Strategy reception at No 10 Downing Street – creating the foundation for brilliant innovation and MedTech

Forte Medical UCI conference

Attending the Greater Irvine Chamber’s 2018 Life Sciences

Giovanna Forte, CEO was delighted to be one of 10 British executives to make their way to UC Irvine (UCI) for the Greater Irvine Chamber’s 2018 Life Science Showcase event.

In collaboration with UCI Applied Innovation, the Greater Irvine Chamber hosted UK owned life science companies to position Southern California and UCI as a strong global brand for innovation and entrepreneurship. Applied Innovation worked closely with the chamber to promote industry cluster growth in the region.

Click here to read more about the event

“Maximising Our Medtech Might”

The NHS National Institute for Health Research (NIHR) will be holding their national industry event on 10th October and our CEO, Giovanna Forte will be participating in the session focusing on “Maximising Our Medtech Might”.

The theme for this year’s event is: The Future Now and provides a platform to discuss the latest developments and opportunities in the UK clinical research environment. We’ll be examining the new era of clinical trials, focussing our lens on patient centricity and asking ‘where is clinical development heading next?’

Click for further information on the NIHR CRN National Industry Event 2018

Making It Work In The USA

The success of the ABHI’s Innovation Hub at the Dell Medical School at the University of Texas in Austin is growing and it is case studies such as ours published this month that is helping demonstrate the importance of the Association’s work in building opportunities for British companies.    Read our story here.

Forte Medical: Series A investment growth round is open

This week saw the launch of Forte Medical’s Series A investment round for growth, export and new product development. Seeking £3.5m, the company is engaging with prospective investment partners who can attract investors with an interest in evidenced, disruptive diagnostic medical devices with digital potential.

Institutional, corporate or personal investors who can assist the business long term are seen as the most promising and attractive partners. For more information, contact our CEO Giovanna Forte.